Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin J Am Soc Nephrol
Autori principali: Provenzano, Robert, Besarab, Anatole, Sun, Chao H., Diamond, Susan A., Durham, John H., Cangiano, Jose L., Aiello, Joseph R., Novak, James E., Lee, Tyson, Leong, Robert, Roberts, Brian K., Saikali, Khalil G., Hemmerich, Stefan, Szczech, Lynda A., Yu, Kin-Hung Peony, Neff, Thomas B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2016
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891748/
https://ncbi.nlm.nih.gov/pubmed/27094610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06890615
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi